FOLFOX therapy has been used for gastric cancer in Japan since 2017. We retrospectively analyzed the efficacy of FOLFOX therapy compared to that of FP. Forty-seven cases were evaluated between January 2010 and December 2018. Eighteen patients received mFOLFOX6 therapy, and 29 patients received FP therapy. The median time to treatment failure was 206 days in the mFOLFOX6 group and 58 days in the FP group. The response rate was 50% in the mFOLFOX6 group and 17% in the FP group. Neutropenia(56%), thrombocytopenia(50%), and peripheral neuropathy(56%)were the common adverse events in the mFOLFOX6 group, and leukopenia(69%)and neutropenia(69%)were the common adverse effects in the FP group. Based on our results, we conclude that, unlike FP, FOLFOX is an effective therapy for of gastric cancer.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effect of Diabetes on Outcomes in Patients With Incurable/Unresectable and Advanced/Recurrent Colorectal Cancer Receiving mFOLFOX6.
Cancer Diagn Progn
January 2025
Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Japan.
Background/aim: The high mortality rate associated with colon cancer in patients with diabetes is well-established; however, the underlying mechanisms have not been fully elucidated. Here, we investigated the efficacy of modified FOLFOX6 (mFOLFOX6) therapy, which is frequently used in colon cancer treatment, in patients with and without comorbid diabetes.
Patients And Methods: The participants in this retrospective cohort study received mFOLFOX6 therapy as a first-line treatment for incurable/ unresectable and advanced/recurrent colon cancer.
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer.
Future Oncol
December 2024
Department of Medical Oncology, Sorbonne Université et Hôpital Saint Antoine, Paris, France.
Patients diagnosed with metastatic colorectal cancer (mCRC) have a poor prognosis with survival ranging 2-3 years. The prevalence of human epidermal growth factor receptor 2 (HER2) amplification is approximately 3-4% in mCRC and increases up to 8% in patients with // wild-type (WT) CRC tumors. Tucatinib is a highly selective HER2-directed tyrosine kinase inhibitor that, in combination with trastuzumab, has demonstrated clinically meaningful activity in patients with chemotherapy-refractory, HER2-positive (HER2+), WT mCRC in the MOUNTAINEER trial.
View Article and Find Full Text PDFPre-operative total neoadjuvant therapy in locally advanced rectal cancer patients: Initial results of Vietnamese patients.
Clin Ter
November 2024
Department of Oncology, Hanoi Medical University, Hanoi, Vietnam.
Article Synopsis
- The study evaluates the effectiveness and safety of total neoadjuvant therapy (TNT) in patients with locally advanced rectal cancer (LARC), focusing on initial results and side effects.
- 75 patients underwent TNT, involving chemoradiation followed by chemotherapy, with a median age of 60.07 and a majority showing advanced tumor stages (T3).
- 33.3% achieved a pathological complete response, with manageable side effects mainly at grades 1 or 2, suggesting TNT is a viable treatment option for LARC.
Modified FOLFOX6 with Cetuximab versus with Radiotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: A Single-Center, Prospective, Randomized Controlled Trial.
Biol Pharm Bull
October 2024
Department of Gastrointestinal Surgery, The Affiliated Ganzhou Hospital of Nanchang University.
Article Synopsis
- A clinical trial assessed the effectiveness of neoadjuvant chemotherapy using targeted agents for locally advanced rectal cancer patients with specific gene mutations.
- Patients were randomly assigned to two treatment groups: one receiving chemotherapy with radiotherapy, and the other with the drug cetuximab; both groups later underwent surgery.
- Results showed no significant differences in the success rates of tumor removal (R0 resection) and other outcomes between the two groups, but the cetuximab group had lower complications, suggesting it may be a better treatment approach.
mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214).
ESMO Open
September 2024
Institut für Pathologie, Speyer, Germany.
Background: Neoadjuvant chemotherapy is an option for patients with locally advanced rectal cancer at low risk for local recurrence. This randomized phase II trial investigated whether the addition of aflibercept to modified FOLFOX6 (mFOLFOX6) could improve the rates of centrally confirmed pathological complete remissions (pCR) and (disease-free) survival in magnetic resonance imaging (MRI)-staged cT3 rectal cancer.
Patients And Methods: Patients with rectal cancer fulfilling the following criteria were included: lower border of tumor >5 cm and <16 cm from anal verge; circumferential resection margin >2 mm and T3-tumor with a maximum infiltration of 10 mm, as determined by MRI.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!